Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
68
KNSA Quote, Financials, Valuation and Earnings
Last price:
$42.55
Seasonality move
:
0.24%
Day range:
$42.29 - $42.99
52-week range:
$17.82 - $44.42
Dividend yield:
0%
P/E ratio:
94.78x
P/S ratio:
5.44x
P/B ratio:
6.02x
Volume:
153.8K
Avg. volume:
389.9K
1-year change:
113.09%
Market cap:
$3.2B
Revenue:
$423.2M
EPS (TTM):
$0.45
Analysts' Opinion
-
Consensus RatingKiniksa Pharmaceuticals International Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $54.71, Kiniksa Pharmaceuticals International Plc has an estimated upside of 28.77% from its current price of $42.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $48.00 representing 100% downside risk from its current price of $42.49.
Fair Value
-
According to the consensus of 6 analysts, Kiniksa Pharmaceuticals International Plc has 28.77% upside to fair value with a price target of $54.71 per share.
KNSA vs. S&P 500
-
Over the past 5 trading days, Kiniksa Pharmaceuticals International Plc has overperformed the S&P 500 by 1.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kiniksa Pharmaceuticals International Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kiniksa Pharmaceuticals International Plc has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Kiniksa Pharmaceuticals International Plc reported revenues of $180.9M.
Earnings Growth
-
Kiniksa Pharmaceuticals International Plc has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Kiniksa Pharmaceuticals International Plc reported earnings per share of $0.23.
Enterprise value:
2.9B
EV / Invested capital:
5.28x
Price / LTM sales:
5.44x
EV / EBIT:
75.44x
EV / Revenue:
4.81x
PEG ratio (5yr expected):
-5.17x
EV / Free cash flow:
28.29x
Price / Operating cash flow:
32.00x
Enterprise value / EBITDA:
72.61x
Gross Profit (TTM):
$315.5M
Return On Assets:
5.78%
Net Income Margin (TTM):
6.01%
Return On Equity:
7.6%
Return On Invested Capital:
7.44%
Operating Margin:
13.28%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $248.7M | $384.1M | $598M | $112.2M | $180.9M | |
| Gross Profit | $166.8M | $233.8M | $315.5M | $62.7M | $97.3M | |
| Operating Income | -$19.2M | -$26.2M | $38.2M | -$9.7M | $24M | |
| EBITDA | -$15M | -$24.7M | $39.6M | -$9.3M | $24.4M | |
| Diluted EPS | -$0.10 | -$0.14 | $0.45 | -$0.18 | $0.23 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $217.5M | $241.8M | $256.1M | $311.3M | $475.5M | |
| Total Assets | $252.9M | $460M | $483.1M | $555.3M | $712.3M | |
| Current Liabilities | $34.4M | $56.5M | $53.5M | $96M | $123.6M | |
| Total Liabilities | $38.8M | $75.9M | $77.9M | $118.3M | $177M | |
| Total Equity | $214M | $384M | $405.1M | $437M | $535.4M | |
| Total Debt | $3.5M | $3.4M | $10.7M | $8.6M | $7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.6M | $11.2M | $102.9M | -$2.2M | $33.7M | |
| Cash From Investing | -$57.3M | -$42.5M | -$52.9M | -$6.3M | -$62.8M | |
| Cash From Financing | $2M | $10.8M | $27.5M | $6.7M | $11.9M | |
| Free Cash Flow | -$2.6M | $11.1M | $101.7M | -$2.2M | $33M | |
KNSA
Sector
Market Cap
$3.2B
$28.1M
Price % of 52-Week High
95.66%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-0.93%
-1.49%
1-Year Price Total Return
113.09%
-17.13%
Beta (5-Year)
0.017
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$42.26
200-day SMA
Buy
Level
$31.90
Bollinger Bands (100)
Buy
Level
34.88 - 41.04
Chaikin Money Flow
Sell
Level
-7.7M
20-day SMA
Buy
Level
$41.66
Relative Strength Index (RSI14)
Buy
Level
58.06
ADX Line
Buy
Level
13.59
Williams %R
Neutral
Level
-44.1635
50-day SMA
Buy
Level
$40.44
MACD (12, 26)
Buy
Level
0.62
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
41.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.7466)
Buy
CA Score
(Annual)
Level (0.8068)
Buy
Beneish M-Score
(Annual)
Level (-2.2887)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.2636)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Stock Forecast FAQ
In the current month, KNSA has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KNSA average analyst price target in the past 3 months is $54.71.
-
Where Will Kiniksa Pharmaceuticals International Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kiniksa Pharmaceuticals International Plc share price will rise to $54.71 per share over the next 12 months.
-
What Do Analysts Say About Kiniksa Pharmaceuticals International Plc?
Analysts are divided on their view about Kiniksa Pharmaceuticals International Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kiniksa Pharmaceuticals International Plc is a Sell and believe this share price will drop from its current level to $48.00.
-
What Is Kiniksa Pharmaceuticals International Plc's Price Target?
The price target for Kiniksa Pharmaceuticals International Plc over the next 1-year time period is forecast to be $54.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KNSA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kiniksa Pharmaceuticals International Plc is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KNSA?
You can purchase shares of Kiniksa Pharmaceuticals International Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kiniksa Pharmaceuticals International Plc shares.
-
What Is The Kiniksa Pharmaceuticals International Plc Share Price Today?
Kiniksa Pharmaceuticals International Plc was last trading at $42.55 per share. This represents the most recent stock quote for Kiniksa Pharmaceuticals International Plc. Yesterday, Kiniksa Pharmaceuticals International Plc closed at $42.49 per share.
-
How To Buy Kiniksa Pharmaceuticals International Plc Stock Online?
In order to purchase Kiniksa Pharmaceuticals International Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get KNSA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KNSA
Sector
P/E ratio
94.78x
23.89x
PEG ratio
-5.17x
-0.01x
P/B ratio
6.02x
1.81x
Price / LTM sales
5.44x
1.59x
Growth Metrics
KNSA
Sector
Revenue growth
61.17%
4.62%
Earnings growth
230.11%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
$0.37
-$0.21
Profitability
KNSA
Sector
Profitability FY 2024
$233.6M
$3.6M
Return on invested capital
7.44%
-31.84%
Return on assets
5.78%
-27.96%
Return on equity
7.6%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Mar
3
Estimated Next Earnings Date
Jan
27
Balance Sheet
KNSA
Sector
Total cash
$352.1M
$26.4M
Short term investments
$60M
$25.7M
Total assets
$580.6M
$76.9M
Long term debt
$7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
56
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
